Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Dual diagnosis and harm reduction
Psychiatry · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Stabilise acute physiology and danger together
Overdose, severe withdrawal, delirium, intoxication, psychosis, mania, suicidal intent, violence, self-neglect or exploitation may occur simultaneously; attributing all risk to either drugs or mental illness creates dangerous delay.
Action: Assess airway, breathing, circulation, glucose, temperature, consciousness and injury while completing an immediate mental-state and safety assessment. Treat overdose or withdrawal, involve crisis and acute medical services at the same time when needed, safeguard dependants, and ensure neither mental-health nor substance services rejects the person because of the other condition.
Overview
Deliver integrated, non-exclusionary care when severe mental illness and substance use coexist, with a shared longitudinal formulation, proportional testing, coordinated treatment sequencing and practical harm reduction that protects life even before abstinence is achieved.
Dual diagnosis describes coexisting mental illness and problematic substance use, but it should not imply two separate people or competing services. Substances may precipitate symptoms, relieve distress briefly, worsen adherence or medication effects, and expose someone to social harm. Psychosis, depression, trauma, ADHD, pain or insomnia may precede use, follow it or share maintaining factors. Begin with a non-judgemental account of what the person hopes each substance does for them and what it costs, alongside strengths, housing, relationships, culture and treatment goals.
NICE recommends reciprocal identification. Ask adults and young people with known or suspected psychosis about alcohol and every prescribed and non-prescribed substance, including quantity, frequency, pattern, route and duration, and assess dependence. Assess people presenting with substance misuse for possible psychosis. Seek corroboration from family or carers with permission when helpful. A timeline across baseline, intoxication, withdrawal, prolonged sleep loss and periods of lower use is more informative than a single positive drug test.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
PsychiatryOriginal SBA
Biological testing in dual diagnosis
A stable patient with psychosis and suspected intermittent substance use is reviewed in clinic. Which approach to urine testing best reflects NICE CG120?
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Care is non-exclusionary. Mental-health services must not refuse psychosis care because substances are used, and substance services must not refuse care because psychosis is present. For most adults with both, secondary mental-health services provide treatment and care coordination for psychosis while drawing on specialist substance advice. Joint working is particularly important with severe alcohol dependence, combined alcohol and benzodiazepine dependence, opioid or cocaine dependence, difficult-to-control use, homelessness or major social disruption. Named responsibilities and direct communication prevent the person falling between thresholds.
Treat both conditions with their evidence-based interventions, then tailor timing to severity, risk, context and readiness. Acute overdose, delirium or withdrawal takes immediate medical priority without postponing suicide or psychosis care. Severe psychosis may initially limit complex psychological work, but engagement, naloxone, substitution treatment, thiamine, nicotine treatment and practical support can begin. NICE finds no special antipsychotic advantage solely because substance misuse coexists; prescribe according to the relevant psychosis or bipolar guideline and interactions. Planned detoxification in psychosis involves substance specialists and generally an inpatient setting.
Harm reduction is active treatment. Offer take-home naloxone and overdose training, avoid solitary use and depressant combinations, use a smaller amount after any abstinence, provide sterile injecting equipment and testing or treatment for HIV and hepatitis, vaccinate where appropriate, and address wounds and sexual health. For alcohol, prevent sudden unsupported withdrawal and give thiamine according to nutritional risk. Maintain opioid substitution across transitions. Agree incremental goals when abstinence is not yet acceptable, review them without punishment and preserve rapid access after relapse or missed appointments.
Key points
Ask everyone with known or suspected psychosis about prescribed and non-prescribed drugs and alcohol, including substance, amount, frequency, pattern, route and duration; assess substance users for psychosis as well.
Do not exclude a person from mental-health care because of substance use or from substance treatment because of psychosis; ongoing use is a clinical need, not a discharge criterion.
Construct a timeline across intoxication, withdrawal, sleep loss, abstinence, mood and psychosis; substance-induced and independent illness can coexist and the formulation may change.
Assess overdose, withdrawal, blood-borne viruses, medication interaction, self-harm, suicide, neglect, violence, exploitation, injury, housing and safeguarding at every meaningful change.
Biological testing can help an agreed clinical question but NICE advises against routine screening tests without consent and an explicit care-plan purpose.
For most adults with psychosis and substance misuse, secondary mental-health services retain care coordination while working jointly with specialist substance services when dependence or complexity warrants it.
Tailor treatment sequence to the relative severity of both conditions, social context and readiness; use standard evidence-based treatment for psychosis because no antipsychotic has special superiority for coexisting substance misuse.
Aetiology
01
Shared vulnerability
Trauma, neurodevelopment, genetics, deprivation and social exclusion can increase risk of both severe mental illness and dependent substance use.
02
Symptom coping
A person may use substances to alter voices, anxiety, insomnia, medication effects or loneliness despite worse longer-term outcomes.
03
Iatrogenic fragmentation
Stigma, rigid service thresholds and poorly coordinated prescriptions can perpetuate recurrent crisis, treatment disengagement, exclusion and unsafe self-medication.
Pathophysiology
1
Neurotransmitter interaction
Dopaminergic, glutamatergic, cannabinoid and stress-system effects can precipitate psychosis or mood symptoms in vulnerable neural networks.
2
Sleep and stress disruption
Intoxication, withdrawal and unstable living conditions disturb sleep and arousal, amplifying paranoia, impulsivity and emotional dysregulation.
3
Treatment interaction
Alcohol and drugs can alter medicine metabolism, adherence and adverse effects, while prescribed sedatives can add overdose risk.
4
Reinforcing cycle
Brief symptom relief reinforces use, followed by rebound distress, social loss and treatment disruption that increases the next urge.
Clinical features and red flags
Substance-induced symptoms
Psychosis, anxiety or mood change closely linked to intoxication, withdrawal or sleep loss may improve with sustained reduction but still needs active treatment.
Independent mental illness
Symptoms preceding substance use or persisting through a credible abstinent interval support a coexisting primary disorder rather than a purely toxic state.
Mutual maintenance
Substances may temporarily blunt voices, trauma or medication adverse effects while rebound symptoms, debt and disrupted sleep increase later distress.
Hidden dependence
Morning use, withdrawal, tolerance, loss of control and prioritisation identify dependence that a simple weekly quantity may miss.
Multiple disadvantage
Homelessness, poverty, racism, trauma, custody, exploitation and fragmented care amplify both conditions and shape what treatment is feasible.
Red flags requiring action
Respiratory depression, reduced consciousness, seizure, delirium, hyperthermia, chest pain or severe autonomic disturbance requires urgent medical treatment before diagnostic debate.
A specific suicide plan, command hallucinations, severe mania, rapidly escalating violence or inability to meet basic needs requires crisis intervention alongside substance care.
Investigations
01Integrated longitudinal interviewFirst step
Why
Map mental symptoms, each substance, medicines, sleep, risk and functioning across exposure and lower-use periods.
Interpretation and limitations
Temporal association informs but rarely proves causation, and the formulation should remain open to coexisting disorders.
02Physical and withdrawal examination
Why
Identify intoxication, respiratory risk, autonomic withdrawal, injection injury, malnutrition and acute medical illness.
Interpretation and limitations
Objective physiology determines emergency treatment and safe detoxification setting before longer-term psychiatric attribution.
03Agreed biological testing
Why
Answer a defined question about exposure, treatment adherence or unexpected clinical change with consent.
Interpretation and limitations
Routine panels miss many substances and show exposure rather than impairment; NICE advises against indiscriminate screening.
04Mental-state and cognitive assessment
Why
Assess psychosis, mood, trauma, cognition, capacity, suicide and violence during repeated contacts.
Interpretation and limitations
Intoxication and withdrawal can alter capacity and presentation, so repeat the assessment after stabilization without withholding immediate safety care.
05
Differential diagnosis
01
Substance-induced psychosis
A tight exposure relationship and resolution with sustained abstinence support causation, although an independent psychosis may later become apparent.
02
Primary psychotic disorder
Symptoms predating use, negative symptoms and persistence outside intoxication or withdrawal support a primary illness that substances may worsen.
03
Delirium and withdrawal
Fluctuating attention, autonomic disturbance and acute physical illness indicate a medical confusional state rather than uncomplicated psychiatric relapse.
04
Trauma and neurodevelopment
Dissociation, hypervigilance, autism, ADHD and cognitive impairment can shape both unusual subjective experiences and the person's substance-related coping patterns.
Management
01Acute presentationRun medical and psychiatric care in parallelFirst stepIntoxication, overdose or withdrawal coincides with psychosis, severe mood symptoms or immediate risk.+
1Stabilise ABC, glucose, temperature and injury and treat the observed toxidrome or withdrawal without waiting for diagnostic certainty.
2Assess suicide, violence, self-neglect, capacity, exploitation and dependants, involving crisis and safeguarding services immediately where needed.
3Document a provisional integrated formulation and arrange direct transfer to teams responsible for both continuing mental-health and substance treatment.
02Ongoing formulationCoordinate rather than refer awaySevere mental illness and recurrent or dependent substance use are both present outside the immediate emergency.+
1Assign a care coordinator, share an agreed plan and seek joint specialist substance input while mental-health treatment continues.
Complications
01
Overdose and withdrawal death
Sedative combinations, reduced tolerance and unsupported alcohol or benzodiazepine cessation create preventable respiratory, seizure and delirium-related acute mortality.
02
Psychiatric relapse
Substance exposure, sleep loss, medication disruption and social crisis can worsen psychosis, mania, depression, suicide and violence risk.
03
Physical health inequality
Blood-borne infection, liver, respiratory and cardiovascular disease are compounded by delayed diagnosis and barriers to ordinary healthcare.
04
Social exclusion
Homelessness, custody, exploitation, family separation and service rejection can become both consequences and drivers of recurrent illness.
Monitoring and follow-up
Review substance pattern, psychosis, mood, sleep, adherence, side effects and functioning together at each care-plan review.
Monitor physical health at least annually in psychosis and more often when substance-related illness risk is significant, with active treatment of findings.
Track naloxone access, sterile-equipment use, infection testing, substitution continuity, thiamine and smoking support as real treatment outcomes.
Audit missed contacts and transitions across hospital, prison, housing and community teams so administrative boundaries do not become clinical exclusion.
Special situations
One timeline beats labels
Mapping symptoms against exposure, withdrawal and sleep clarifies causal hypotheses while allowing both primary illness and substance effects to remain true.
Use is not exclusion
Continued substance use often signals unmet treatment need and risk; discharging for it increases the very harms services should reduce.
Testing needs a question
A result is useful when it changes care and is understood by the person, not when collected routinely as surveillance.
Small goals protect life
Naloxone, avoiding solitary use and maintaining substitution treatment can prevent death while motivation for larger change develops.
Transitions multiply risk
Tolerance loss, missed prescriptions and lost care coordination make hospital discharge and prison release especially dangerous periods.
Common pitfalls
01
Refusing mental-health care until abstinence or refusing substance care until psychosis is stable.
02
Attributing every hallucination to drugs or every substance use episode to a primary psychiatric disorder.
03
Using routine urine testing without consent, a clinical question or awareness of assay limits.
04
Choosing an antipsychotic because it is claimed to have unique anti-addiction effects rather than following the relevant psychosis guideline.
05
Planning alcohol, benzodiazepine or complex polydrug detoxification without the setting and specialists required for withdrawal risk.
06
Withholding harm reduction because the person is not ready for abstinence or has relapsed.
Harm reduction includes naloxone, sterile equipment, hepatitis and HIV testing and treatment, safer-sex care, avoiding sedative combinations and solitary use, dose reduction after abstinence, thiamine and continuity of opioid substitution.
Alcohol or benzodiazepine dependence with sudden reduction carries seizure and delirium risk; opioid abstinence or missed substitution treatment raises overdose risk on return.
Homelessness, coercion, sexual exploitation, domestic abuse, dependent children or cognitive impairment requires an explicit safeguarding and practical response.
Planned detoxification in a person with psychosis should involve specialist substance services and usually occur in an appropriate inpatient setting as part of the overall care plan.
Comprehensive health and social screen
Why
Offer blood-borne-virus, liver, pregnancy and sexual-health assessment and document housing, finance, family and safeguarding needs.
Interpretation and limitations
Positive findings require linked treatment and practical intervention, not a reason to delay or deny psychiatric or substance care.
2
Offer standard evidence-based treatment for each condition, sequencing interventions according to changing severity, social context and readiness.
3Use consented, question-led testing and repeated timelines to refine diagnosis, medication interactions, goals and relapse planning.
03Harm reductionReduce mortality before abstinenceThe person continues to use, declines a current abstinence goal or is at high risk around relapse and transitions.+
1Provide naloxone, sterile equipment, infection care, safer-use and sedative-combination advice, thiamine and substitution treatment as indicated.
2Plan for reduced tolerance after hospital, prison, detoxification or any gap, and verify uninterrupted opioid substitution prescribing.
3Agree attainable next steps for housing, nutrition, medicines, contact and substance reduction, reviewing progress without exclusion after lapse.